Back to school for biotech, Biogen’s potential pivot, & Illumina’s next chapter

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Dexcom hails CGM share gains as driver of 25% revenue growth in Q2

By the numbers Q2 Revenue: $871.3 million 25% increase year-over-year Q2 Net income: $115.9 million 128% increase year-over-year Q2 Insights Dexcom’s international market share gains

July 28, 2023

Philips Receives FDA 510(k) Clearance on Image-Guided Surgical Therapy

What You Should Know: – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its Philips Zenition 30 mobile C-arm has

April 24, 2024

MYO1D mutation identified as a key factor in sperm defects and congenital conditions

The research uncovers a novel variant in the MYO1D gene that is linked to laterality defects, congenital heart diseases, and sperm defects in humans.

September 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.